摘要
目的:筛选头颈部鳞状细胞癌预后相关的铜死亡相关基因并对其进行药物敏感性分析.方法:通过对TCGA数据库中的HNSCC样本进行突变基因筛选,挑选出铜死亡相关基因并对其进行药物敏感与耐药分析.结果:在 23 个HNSCC突变率 10%及以上的基因中,CDKN2A、CSMD3 和RYR2 为HNSCC突变关键基因.13 个铜死亡相关基因中,CDKN2A、GLS和ATP7B为预后相关的关键基因.对HNSCC中CDKN2A基因敏感的药物包括Thapsi-gargin、ACY-1215(Rocilinostat)和Trichostatin A,有较高抵抗的药物包括Palbociclib、Nutlin-3a、Platin、SJ-172550、carbazochrome和bambuterol.结论:铜死亡相关基因CDKN2A与HNSCC的 5 年生存率高度相关,并且可能对抗肿瘤药物Thapsigargin、ACY-1215(Rocilinostat)和Trichostatin A敏感.
Abstract
Objective To identify cuproptosis-related genes associated with prognosis in head and neck squamous cell carci-noma(HNSCC)and analyze their drug sensitivity.Methods Mutant genes in HNSCC samples obtained from the TCGA da-tabase were screened to select cuproptosis-related genes for drug sensitivity and resistance analysis.Results Among the 23 genes with a mutation rate of 10%or above in HNSCC,CDKN2A,CSMD3,and RYR2 were identified as key genes.Among the 13 cuproptosis-related genes,CDKN2A,GLS,and ATP7B were identified as key genes associated with prognosis.Drugs sensitive to the CDKN2A in HNSCC included Thapsigargin,ACY-1215(Rocilinostat),and Trichostatin A,while drugs with high resistance included Palbociclib,Nutlin-3a,Platin,SJ-172550,carbazochrome,and bambuterol.Conclu-sion CDKN2A is highly correlated with the 5-year survival of HNSCC and is sensitive to anti-tumor drugs Thapsigargin,ACY-1215(Rocilinostat),and Trichostatin A.
维普
万方数据